BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feng LY, Li L. Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer. J Ovarian Res 2020;13:35. [PMID: 32228639 DOI: 10.1186/s13048-020-00635-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Konrad SM, Schwamborn K, Krüger A, Honert K, Schmitt M, Hellmann D, Schmalfeldt B, Meindl A, Kiechle M, Quante AS, Brambs C, Grill S, Ramser J. NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer. Biomarkers in Medicine 2022. [DOI: 10.2217/bmm-2021-0781] [Reference Citation Analysis]
2 Pan S, Deng Y, Fu J, Zhang Y, Zhang Z, Qin X. N6‑methyladenosine upregulates miR‑181d‑5p in exosomes derived from cancer‑associated fibroblasts to inhibit 5‑FU sensitivity by targeting NCALD in colorectal cancer. Int J Oncol 2022;60:14. [PMID: 35014676 DOI: 10.3892/ijo.2022.5304] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
3 Liu S, Wu M, Wang F. Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer. J Cancer 2021;12:3976-96. [PMID: 34093804 DOI: 10.7150/jca.47695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]